2023
DOI: 10.3389/fphar.2023.1130937
|View full text |Cite
|
Sign up to set email alerts
|

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Abstract: Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 137 publications
0
2
0
Order By: Relevance
“…New synthetic biology approaches allow for the direct delivery of payloads by cancer-specific, natural or synthetic nanoparticles capable of targeting tumor cell surface antigens [ 48 ]. These payloads can induce regulated cell death of cancer cells directly, while simultaneous transgenic expression of immune modifiers (before the death of the same cancer cells) can exponentially activate the relevant players of the MCN in the TME [ 81 83 ] (Fig. 1 B).…”
Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning
confidence: 99%
“…New synthetic biology approaches allow for the direct delivery of payloads by cancer-specific, natural or synthetic nanoparticles capable of targeting tumor cell surface antigens [ 48 ]. These payloads can induce regulated cell death of cancer cells directly, while simultaneous transgenic expression of immune modifiers (before the death of the same cancer cells) can exponentially activate the relevant players of the MCN in the TME [ 81 83 ] (Fig. 1 B).…”
Section: Direct (Primary) Versus Indirect (Secondary) Cancer Cell Kil...mentioning
confidence: 99%
“…For instance, the use of anti-angiogenic agents can disrupt the blood supply to the tumor, thereby weakening its growth and survival. [ 50 ] Additionally, inhibitors that target immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, can potentially rejuvenate the immune response within the tumor microenvironment. [ 51 ] By employing these strategies, the aim is to reshape the tumor milieu, making it more conducive for immune cells to operate effectively.…”
Section: Overcoming Drug Resistance In Gi Cancer Immunotherapymentioning
confidence: 99%